TOP > 外国特許検索 > Activator for mesenchymal stem cells activated mesenchymal stem cells and method for producing same

Activator for mesenchymal stem cells activated mesenchymal stem cells and method for producing same NEW

外国特許コード F180009487
整理番号 13008-KR01
掲載日 2018年10月30日
出願国 大韓民国
出願番号 20167028290
公報番号 20160131112
出願日 平成27年3月11日(2015.3.11)
公報発行日 平成28年11月15日(2016.11.15)
国際出願番号 JP2015057217
国際公開番号 WO2015137419
国際出願日 平成27年3月11日(2015.3.11)
国際公開日 平成27年9月17日(2015.9.17)
優先権データ
  • 20140-048202 JP
  • 2015JP57217 (2015.3.11) WO
発明の名称 (英語) Activator for mesenchymal stem cells activated mesenchymal stem cells and method for producing same NEW
発明の概要(英語) [Subject] the remedial value loss or reduction, or rather the liver lobe which is unusual has a diseased deterioration effect the stem cell to cell transplant medical therapy at the time of activation as for height is thing in goal in the suitable situation. [Solution means] this invention the liver lobe stem cell active topic, by a minute description active topic the liver lobe which is activated the stem cell and his manufacturing method, and the liver lobe which is activated the stem cell the low of including about the medicine is the thing.
従来技術、競合技術の概要(英語) Background Art
As for the number of diabetics increase be with to be walking whole world, the diabetes as for under bringing about is caused with the hyperglycemia which is chronic and as for under occurring the various complication QOL and life of the patient as for under threatening is becoming the serious problem.
The diabetes which is called in three generations complication of diabetes the new symptoms, diabetic retina symptoms and the diabetic neuropathy all capillary in the center is a military register change which happens to the narrow blood vessel.Because of thin small blood vessel obstacle becomes the obstacle of long term, became ill.Such complication appropriately controls the blood glucose with diet medical therapy and medication with which degree will be able to prevent, as for the case which meantime is different the complication does severe anger the cure which is basic does not exist.
The liver lobe the stem cell (Mesenchymal stem cell, even as also below MSC the box) not only the mesenchymal cell will go over the germ layer, will be able to differentiate in the various cell to be a cell, and organization occurrence and recoveryRemaking the low of controlling known the fact that had an ability.
The liver lobe as for the stem cell the separation cultivation easy will be able to secure the number of implantation possible cells to the multiplication decline excellent short term the own implantation which is not the immunity refusal to be possible, also the ethical problem to be few, and with the low immunogenicity former handle in necessity the similar implantation real be because about the various disease the review of treatment application is processed with the material of the cell transplant medical therapy which is an ideal.
For example, diabetes and the complication above (non-patent literature 1 and 2) besides the brainCardiovascular disease (patent literature 1), autoimmune dieases (non-patent literature 3), the multiple sclerosis the experimental, immunity encephalomyelitis model (non-patent literature 4), inflammation disease (about the lung fibrosis model non-patent literature 5, about inflammation market disease non-patent literature 6) from disease the liver lobe the remedial value of the stem cell is confirmed.
As for under using case, the liver lobe which maintained the fixed quality there is a necessity which will prepare the stem cell at the quick large quantity in treatment of disease.From Donner the liver lobe which picked in order the stem cell from the organism outside at the time of multiplication height the growth promotion material or the various review cultivation record to be become accomplished, from patent literature 2 the umbilical cord extract from the bloodless blue badge at the time of stem cell cultivation be is started for example serviceable re-with serum substitutional.Also about quality of the cell, for example from patent literature 3 at the time of total large cultivation the liver lobe, suppresses aging of the stem cell the cell proliferation badge for is started.
But, the umbilical cord extract which is started to patent literature 2 did not pass re-to serum substitutional, and also the patent literature 3 from organism external multiplication the liver lobe quality of the stem cell suppressing the degree of maintenance or deterioration to be in goal do, and from picking point of view suitable to therapeutic use, be so called the liver lobe of that quality, quality of the stem cell as for under improving or the fringe land was not the thing.
Citation List
Patent literature
International opening to the public WO2005/007176 good pamphlet
International opening to the public WO2013/009100 good pamphlet
Japanese patent opening to the public public information 2006-325444th unit
Non patent literature
Ezquer, F - E - et aluminum., Biol Blood Marrow Transplant 2008; 14 (6): 631-40
Lee, R - H - et aluminum., Proc Natl Acad Sci USA 2006; 103 (46): 17438-43
Djouad, F - et aluminum., Arthritis Rheum 2005; 52 (5): 1595-1603
Zappia E - et aluminum., Blood 2005; 106: 1755-1761
Ortiz, A - L - et aluminum., Proc Natl Acad Sci USA, 2003; 100 (14): 8407-8411
Tanaka H - et aluminum., J Gastroenterol 2011; 46: 143-152
特許請求の範囲(英語) [claim1]
1. The extract of the fetus belongings of the mammal with the effectiveness person as for under containing the liver lobe which is unusual active topic of the stem cell.
[claim2]
2. There is in a 1st claim, and the fetus belongings umbilical cord organization, the liver lobe which is unusual is a placenta organization or a egg membrane active topic of the stem cell.
[claim3]
3. Is in the 1st claim or the second claim, and the minute description extract the liver lobe which is unusual does not include the cell which has the multiplication royal tomb of minute description mammal origin active topic of the stem cell.
[claim4]
4. The 1st claim to there is in which one claim in the 3rd claim, and minute description the liver lobe which is unusual the stem cell the bone marrow origin liver lobe the liver lobe which is unusual is a stem cell active topic of the stem cell.
[claim5]
5. Is in the 1st claim to which one claim in the fourth claim, and minute description the liver lobe which is unusual the liver lobe which is unusual is that the stem cell separates from diseased target active topic of the stem cell.
[claim6]
6. There is in a fifth claim, and minute description disease diabetes, autoimmune dieases and chronic inflammation disease, the liver lobe which is unusual is an allergie disease or a osteoporosis active topic of the stem cell.
[claim7]
7. There is in a fifth claim, and the liver lobe which is unusual the minute description disease is diabetes or arthritis active topic of the stem cell.
[claim8]
8. The liver lobe which is unusual separates from target the stem cell the extract of the fetus belongings of the mammal with the effectiveness person as for under containing as for under activation zero controlling process as for under including the liver lobe which is activated manufacturing method of the stem cell.
[claim9]
9. There is in a 8th claim, and minute description the liver lobe which is unusual the stem cell the bone marrow origin liver lobe the liver lobe which is a stem cell manufacturing method of the stem cell.
[claim10]
10. The 8th claim or there is in a 9th claim, and the liver lobe where the minute description target is diseased target manufacturing method of the stem cell.
[claim11]
11. There is in a 10th claim, and minute description disease diabetes, autoimmune dieases and chronic inflammation disease, the liver lobe which is an allergie disease or a osteoporosis manufacturing method of the stem cell.
[claim12]
12. There is in a 10th claim, and the liver lobe where the minute description disease is diabetes or arthritis manufacturing method of the stem cell.
[claim13]
13. The 8th claim to in the 12th claim by the method which is recorded to which one claim the diseased treatment which is manufactured and/or the preventive suspicion liver lobe the stem cell.
[claim14]
14. There is in a 13th claim, and minute description disease diabetes or the complication, immunity disease and chronic inflammation disease, the liver lobe which is an allergie disease or a osteoporosis the stem cell.
[claim15]
15. There is in a 13th claim, and minute description disease diabetes the new symptoms, diabetic retina symptoms, the liver lobe which is a diabetic neurological disorder or a rheumatoid arthritis the stem cell.
[claim16]
16. The 13th claim to in the 15th claim the liver lobe which is recorded to which one claim the stem cell and/or his cultivation will ask the low of including diseased treatment and/or the preventive medicine.
  • 出願人(英語)
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • FUJIMIYA MINEKO
  • NAGAISHI KANNA
  • MIZUE YUKA
  • CHIKENJI TAKAKO
国際特許分類(IPC)

PAGE TOP

close
close
close
close
close
close